プロフィール詳細

プロジェクトを作成

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

Dr. Guillaume B.に依頼

Canada

Pharma & Life Sciences Consultant | Scientifc Writing | Data Analysis | Project & Risk management

プロフィール概要

Clinical research professional and PhD-trained biologist with over 13 years of experience across preclinical, early-phase, and Phase 3 clinical studies in oncology, immunology, and respiratory diseases. I have led and coordinated complex, cross-functional clinical research projects in both academic and industry settings, working closely with investigators, sponsors, CROs, and regulatory bodies. My expertise includes scientific and medical writing, protocol and feasibility assessment, evidence synthesis, and interpretation of clinical and operational data. I am highly experienced in translating complex clinical and research data into clear, structured, and decision-ready documents for diverse stakeholders, including investigators, sponsors, and regulatory teams. With hands-on experience in data capture systems, clinical databases, and trial management tools, I bring a rigorous, detail-oriented approach to data analysis, documentation, and quality oversight. My background spans the full research continuum—from bench to bedside—allowing me to support biotech, pharma, and research organizations with high-quality scientific content, data-driven insights, and research strategy support.

専門分野

• ☆ Microbiology
• ☆ Molecular Biology
• ☆ RNA Synthesis
• ☆ Ecology
• ☆ Clinical Microbiology
• ☆ Vaccine Development
• ☆ Clinical Trials
• ☆ Clinical Trial Design
• ☆ Patient Recruitment
• ☆ Clinical Data Management
• ☆ Clinical Trials Data Analysis
• ☆ Oncology
• ☆ Radiation Therapy
• ☆ Regulatory Affairs
• ☆ Pharmaceutical Management
• ☆ Pharmaceutical Technology
• ☆ Six Sigma

サービス

• Writing
• Research
• Consulting
• Data & AI
• Product Development

Writing Clinical Trial Documentation, Medical Writing

Research Meta-Research, Feasibility Study, Scientific and Technical Research

Consulting Healthcare Consulting

Data & AI Statistical Analysis, Image Processing, Image Analysis

Product Development Product Evaluation, Product Validation, Manufacturing

職務経験

Syneos Health (United States)

- 現在

Clinical Study Manager

Syneos Health (Previously INCResearch)

10月 2023 - 11月 2025

Clinical Site Manager

CHU de Quebec

5月 2018 - 10月 2023

Clinical Site manager and research associate

IRCM

1月 2012 - 5月 2018

学歴

certificate

Université Laval - Canada

1月 2011 - 7月 2011

PhD (biology)

Université Laval

5月 2003 - 12月 2007

認定資格

• Certified Risk Management Expert | ISO 31000

  Sigma Six

  1月 2026 - 現在

• Certified White/Yellow Belt

  Sigma Six - Université Laval

  6月 2020 - 現在

出版物

JOURNAL ARTICLE

Pouliot F, Saad F, Rousseau E, Richard PO, Zamanian A, Probst S, Lévesque É, Castonguay V, Marcoux N, Lodde M, et al. (2024). Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study . Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Desy A, Bouvet GF, Lafrenière N, Zamanian A, Després P, Beauregard JM (2022). Impact of the dead-time correction method on quantitative ¹⁷⁷Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy . EJNMMI physics.

Pouliot F, Beauregard JM, Saad F, Trudel D, Richard PO, Turcotte É, Rousseau É, Probst S, Kassouf W, Anidjar M, et al. (2021). The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol . BJU international.

Desy A, Bouvet GF, Croteau É, Lafrenière N, Turcotte ÉE, Després P, Beauregard JM (2021). Quantitative SPECT (QSPECT) at high count rates with contemporary SPECT/CT systems . EJNMMI physics.

Bouvet GF, Bulka O, Coriati A, Sognigbé L, St-Pierre G, Massé C, Sato S, Berthiaume Y (2021). Peripheral blood mononuclear cell response to YKL-40 and Galectin-3 in cystic fibrosis . Cytokine.

Coriati A, Bouvet GF, Massé C, Ducruet T, Berthiaume Y (2020). YKL-40 as a clinical biomarker in adult patients with CF: Implications of a CHI3L1 single nucleotide polymorphism in disease severity . Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Desy A, Bouvet GF, Frezza A, Després P, Beauregard JM (2020). Impact of dead time on quantitative ¹⁷⁷Lu-SPECT (QSPECT) and kidney dosimetry during PRRT . EJNMMI physics.

Bouvet GF, Voisin G, Cyr Y, Bascunana V, Massé C, Berthiaume Y (2018). DNA Methylation Regulates RGS2-induced S100A12 Expression in Airway Epithelial Cells . American journal of respiratory cell and molecular biology.

Coriati A, Massé C, Ménard A, Bouvet GF, Berthiaume Y (2018). Neutrophils as a Potential Source of Chitinase-3-like Protein 1 in Cystic Fibrosis . Inflammation.

Coriati A, Arslanian E, Bouvet GF, Prat A, Seidah NG, Rabasa-Lhoret R, Berthiaume Y (2017). Proprotein Convertase Subtilisin/Kexin type 9 affects insulin but not lipid metabolism in cystic fibrosis . Clinical and investigative medicine. Medecine clinique et experimentale.

Beaudoin N, Bouvet GF, Coriati A, Rabasa-Lhoret R, Berthiaume Y (2017). Combined Exercise Training Improves Glycemic Control in Adult with Cystic Fibrosis . Medicine and science in sports and exercise.

Bouvet GF, Maignan M, Arslanian E, Coriati A, Rabasa-Lhoret R, Berthiaume Y (2014). Association between serum YKL-40 level and dysglycemia in cystic fibrosis . Cytokine.

Boncoeur É, Bouvet GF, Migneault F, Tardif V, Ferraro P, Radzioch D, de Sanctis JB, Eidelman D, Govindaraju K, Dagenais A, et al. (2013). Induction of nitric oxide synthase expression by lipopolysaccharide is mediated by calcium-dependent PKCα-β1 in alveolar epithelial cells . American journal of physiology. Lung cellular and molecular physiology.

Bouvet GF, Jacobi V, Plourde KV, Bernier L (2007). Stress-induced mobility of OPHIO1 and OPHIO2, DNA transposons of the Dutch elm disease fungi . Fungal genetics and biology : FG & B.